Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Eldad Melamed

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Cerebrovascular Circulation

Concepts & Ideas

Time Factors

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
79
Offen, Daniel
56
Djaldetti, Ruth
49
Ziv, Ilan
27
Barzilai, Ari
18
Shirvan, Anat
16
Barhum, Yael
14
Gilgun-Sherki, Yossi
11
Achiron, Anat
11
Panet, Hana
10
Zoldan, J
9
Zilkha-Falb, Rina
9
Levy, Yossef
9
Merims, Doron
8
Lev, Nirit
7
Lev, Nirit

Sign-in to see all Coauthors

Publications

TOP 3
Sadan Ofer; Melamed Eldad; Offen Daniel
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.
Barzilay Ran; Melamed Eldad; Offen Daniel
Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible.
Sadan Ofer; Bahat-Stromza Merav; Barhum Yael; Levy Yossef S; Pisnevsky Anat; Peretz Hagit; Ilan Avihay Bar; Bulvik Shlomo; Shemesh Noam; Krepel Dana; Cohen Yoram; Melamed Eldad; Offen Daniel
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Eldad Melamed (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Sadan Ofer; Melamed Eldad; Offen Daniel
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.
Expert opinion on biological therapy 2009;9(12):1487-97.
2009: Barzilay Ran; Melamed Eldad; Offen Daniel
Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible.
Stem cells (Dayton, Ohio) 2009;27(10):2509-15.
2009: Sadan Ofer; Bahat-Stromza Merav; Barhum Yael; Levy Yossef S; Pisnevsky Anat; Peretz Hagit; Ilan Avihay Bar; Bulvik Shlomo; Shemesh Noam; Krepel Dana; Cohen Yoram; Melamed Eldad; Offen Daniel
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.
Stem cells and development 2009;18(8):1179-90.
2009: Olanow C Warren; Rascol Olivier; Hauser Robert; Feigin Paul D; Jankovic Joseph; Lang Anthony; Langston William; Melamed Eldad; Poewe Werner; Stocchi Fabrizio; Tolosa Eduardo;
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
The New England journal of medicine 2009;361(13):1268-78.
2009: Bahat-Stroomza Merav; Barhum Yael; Levy Yossef S; Karpov Olga; Bulvik Shlomo; Melamed Eldad; Offen Daniel
Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.
Journal of molecular neuroscience : MN 2009;39(1-2):199-210.
2009: Lev Nirit; Ickowicz Debby; Barhum Yael; Melamed Eldad; Offen Daniel
DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS.
Journal of molecular neuroscience : MN 2009;38(2):94-102.
2009: Offen Daniel; Barhum Yael; Melamed Eldad; Embacher Norbert; Schindler Christoph; Ransmayr Gerhard
Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant.
Journal of molecular neuroscience : MN 2009;38(2):85-93.
2009: Barzilay Ran; Ben-Zur Tali; Bulvik Shlomo; Melamed Eldad; Offen Daniel
Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells.
Stem cells and development 2009;18(4):591-601.
2009: Sadan Ofer; Shemesh Noam; Cohen Yoram; Melamed Eldad; Offen Daniel
Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases.
The Israel Medical Association journal : IMAJ 2009;11(4):201-4.
2009: Djaldetti Ruth; Lev Nirit; Melamed Eldad
Lesions outside the CNS in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2009;24(6):793-800.
2009: Giladi Nir; Tal Joseph; Azulay Tali; Rascol Oliver; Brooks David J; Melamed Eldad; Oertel Wolfgang; Poewe Werner H; Stocchi Fabrizio; Tolosa Eduardo
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2009;24(5):655-61.
2009: Lev Nirit; Ickowicz Debby; Barhum Yael; Lev Shaul; Melamed Eldad; Offen Daniel
DJ-1 protects against dopamine toxicity.
Journal of neural transmission (Vienna, Austria : 1996) 2009;116(2):151-60.
2009: Barzilay Ran; Sadan Ofer; Melamed Eldad; Offen Daniel
Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains.
Cytotherapy 2009;11(4):435-42.
2008: Yust-Katz Shlomit; Tesler Debora; Treves Theres A; Melamed Eldad; Djaldetti Ruth
Handedness as a predictor of side of onset of Parkinson's disease.
Parkinsonism & related disorders 2008;14(8):633-5.
2008: Olanow C Warren; Hauser Robert A; Jankovic Joseph; Langston William; Lang Anthony; Poewe Werner; Tolosa Eduardo; Stocchi Fabrizio; Melamed Eldad; Eyal Eli; Rascol Olivier
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Movement disorders : official journal of the Movement Disorder Society 2008;23(15):2194-201.
2008: Sadan Ofer; Shemesh Noam; Barzilay Ran; Bahat-Stromza Merav; Melamed Eldad; Cohen Yoram; Offen Daniel
Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging.
Stem cells (Dayton, Ohio) 2008;26(10):2542-51.
2008: Djaldetti R; Hassin-Baer S; Farrer M J; Vilariño-Güell C; Ross O A; Kolianov V; Yust-Katz S; Treves T A; Barhum Y; Hulihan M; Melamed E
Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(9):1279-84.
2008: Funayama Manabu; Li Yuanzhe; Tsoi Tak-Hong; Lam Ching-Wan; Ohi Takekazu; Yazawa Shogo; Uyama Eiichiro; Djaldetti Ruth; Melamed Eldad; Yoshino Hiroyo; Imamichi Yoko; Takashima Hiroshi; Nishioka Kenya; Sato Kenichi; Tomiyama Hiroyuki; Kubo Shin-Ichiro; Mizuno Yoshikuni; Hattori Nobutaka
Familial Parkinsonism with digenic parkin and PINK1 mutations.
Movement disorders : official journal of the Movement Disorder Society 2008;23(10):1461-5.
2008: Barzilay Ran; Kan Inna; Ben-Zur Tali; Bulvik Shlomo; Melamed Eldad; Offen Daniel
Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols.
Stem cells and development 2008;17(3):547-54.
2008: Lev Nirit; Ickowicz Debby; Melamed Eldad; Offen Daniel
Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.
Neurotoxicology 2008;29(3):397-405.
2008: Yust-Katz Shlomit; Sthneer Sonia; Melamed Eldad; Djaldetti Ruth
Long-term Parkinson's disease--time for optimism.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2008;62(4):233-5.
2008: Hellmann Mark A; Sabach Tilda; Melamed Eldad; Djaldetti Ruth
Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2008;62(4):250-2.
2008: Levy Y S; Bahat-Stroomza M; Barzilay R; Burshtein A; Bulvik S; Barhum Y; Panet H; Melamed E; Offen D
Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease.
Cytotherapy 2008;10(4):340-52.
2008: Djaldetti R; Nageris B I; Lorberboym M; Treves T A; Melamed E; Yaniv E
[(123)I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(3):469-72.
2007: Djaldetti Ruth; Treves Therese A; Ziv Ilan; Melamed Eldad; Lorberboym Mordechai
123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity?
Journal of nuclear medicine technology 2007;35(4):232-6.
2007: Melamed Eldad; Ziv Ilan; Djaldetti Ruth
Management of motor complications in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2007;22 Suppl 17():S379-84.
2007: Djaldetti Ruth; Yust-Katz Shlomit; Kolianov Vadim; Melamed Eldad; Dabby Ron
The effect of duloxetine on primary pain symptoms in Parkinson disease.
Clinical neuropharmacology 2007;30(4):201-5.
2007: Litvan Irene; Chesselet Marie-Francoise; Gasser Thomas; Di Monte Donato A; Parker Davis; Hagg Theo; Hardy John; Jenner Peter; Myers Richard H; Price Donald; Hallett Mark; Langston William J; Lang Anthony E; Halliday Glenda; Rocca Walter; Duyckaerts Charles; Dickson Dennis W; Ben-Shlomo Yoav; Goetz Christopher G; Melamed Eldad
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.
Journal of neuropathology and experimental neurology 2007;66(5):329-36.
2007: Kan Inna; Ben-Zur Tali; Barhum Yael; Levy Yossef S; Burstein Alex; Charlow Tirza; Bulvik Shlomo; Melamed Eldad; Offen Daniel
Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression.
Neuroscience letters 2007;419(1):28-33.
2007: Abraham Alon; Elena Cogan; Melamed Eldad; Djaldetti Ruth
Successful treatment of truncal myoclonus.
Movement disorders : official journal of the Movement Disorder Society 2007;22(7):1055-6.
2007: Reshef Ayelet; Shirvan Anat; Grimberg Hagit; Levin Galit; Cohen Avi; Mayk Adi; Kidron Debora; Djaldetti Ruth; Melamed Eldad; Ziv Ilan
Novel molecular imaging of cell death in experimental cerebral stroke.
Brain research 2007;1144():156-64.
2007: Litvan Irene; Halliday Glenda; Hallett Mark; Goetz Christopher G; Rocca Walter; Duyckaerts Charles; Ben-Shlomo Yoav; Dickson Dennis W; Lang Anthony E; Chesselet Marie-Francoise; Langston William J; Di Monte Donato A; Gasser Thomas; Hagg Theo; Hardy John; Jenner Peter; Melamed Eldad; Myers Richard H; Parker Davis; Price Donald L
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.
Journal of neuropathology and experimental neurology 2007;66(4):251-7.
2007: Kan Inna; Melamed Eldad; Offen Daniel; Green Pnina
Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation.
Journal of lipid research 2007;48(3):513-7.
2007: Grunfeld Jonathan F; Barhum Yael; Blondheim Netta; Rabey Jose-Martin; Melamed Eldad; Offen Daniel
Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.
Experimental neurology 2007;204(1):260-3.
2007: Lev Nirit; Melamed Eldad; Offen Daniel
Toxic causes of parkinsonism.
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn 2007;84():385-98.
2007: Koller William C; Melamed Eldad
Preface.
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn 2007;84():IX.
2007: Djaldetti Ruth; Melamed Eldad
Sensory symptoms in Parkinson's disease.
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn 2007;83():377-84.
2007: Koller William C; Melamed Eldad
Preface.
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn 2007;83():IX.
2007: Offen D; Barhum Y; Levy Y S; Burshtein A; Panet H; Cherlow T; Melamed E
Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease.
Journal of neural transmission. Supplementum 2007;(72):133-43.
2007: Kan I; Melamed E; Offen D
Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases.
Handbook of experimental pharmacology 2007;(180):219-42.
2006: Djaldetti R; Lorberboym M; Melamed E
Primary postural instability: a cause of recurrent sudden falls in the elderly.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2006;27(6):412-6.
2006: Melamed Eldad; Djaldetti Ruth
Camptocormia in Parkinson's disease.
Journal of neurology 2006;253 Suppl 7():VII14-16.
2006: Djaldetti R; Melamed E
Camptocormia in Parkinson's disease: new insights.
Journal of neurology, neurosurgery, and psychiatry 2006;77(11):1205.
2006: Lev Nirit; Ickowicz Debby; Barhum Yael; Blondheim Netta; Melamed Eldad; Offen Daniel
Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis.
Antioxidants & redox signaling 2006;8(11-12):1987-95.
2006: Hellmann Mark A; Djaldetti Ruth; Israel Zvi; Melamed Eldad
Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(11):2008-10.
2006: Djaldetti Ruth; Ziv Ilan; Melamed Eldad
The mystery of motor asymmetry in Parkinson's disease.
Lancet neurology 2006;5(9):796-802.
2006: Dabby R; Djaldetti R; Shahmurov M; Treves T A; Gabai B; Melamed E; Sadeh M; Avinoach I
Skin biopsy for assessment of autonomic denervation in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(9):1169-76.
2006: Oved Daniel; Ziv Ilan; Treves Therese A; Paleacu Diana; Melamed Eldad; Djaldetti Ruth
Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(8):1257-61.
2006: Tomiyama Hiroyuki; Li Yuanzhe; Funayama Manabu; Hasegawa Kazuko; Yoshino Hiroyo; Kubo Shin-Ichiro; Sato Kenichi; Hattori Tatsuya; Lu Chin-Song; Inzelberg Rivka; Djaldetti Ruth; Melamed Eldad; Amouri Rim; Gouider-Khouja Neziha; Hentati Faycal; Hatano Yasuko; Wang Mei; Imamichi Yoko; Mizoguchi Koichi; Miyajima Hiroaki; Obata Fumiya; Toda Tatsushi; Farrer Matthew J; Mizuno Yoshikuni; Hattori Nobutaka
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
Movement disorders : official journal of the Movement Disorder Society 2006;21(8):1102-8.
2006: Lev Nirit; Melamed Eldad; Offen Daniel
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Neuroscience letters 2006;399(1-2):27-32.
2006: Blondheim Netta R; Levy Yossef S; Ben-Zur Tali; Burshtein Alex; Cherlow Tirza; Kan Inna; Barzilai Ran; Bahat-Stromza Merav; Barhum Yael; Bulvik Shlomo; Melamed Eldad; Offen Daniel
Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.
Stem cells and development 2006;15(2):141-64.
2006: Lorberboym Mordechai; Treves Therese A; Melamed Eldad; Lampl Yair; Hellmann Mark; Djaldetti Ruth
[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(4):510-4.
2006: Hellmann M A; Panet H; Barhum Y; Melamed E; Offen D
Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents.
Neuroscience letters 2006;395(2):124-8.
2006: Barzilay Ran; Levy Yossef S; Melamed Eldad; Offen Daniel
Adult stem cells for neuronal repair.
The Israel Medical Association journal : IMAJ 2006;8(1):61-6.
2006: Lev Nirit; Roncevic Dusan; Ickowicz Debby; Melamed Eldad; Offen Daniel
Role of DJ-1 in Parkinson's disease.
Journal of molecular neuroscience : MN 2006;29(3):215-25.
2006: Gilgun-Sherki Yossi; Melamed Eldad; Offen Daniel
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.
Current pharmaceutical design 2006;12(27):3509-19.
2005: Sadan Ofer; Bahat-Stromza Merav; Gilgun-Sherki Yossi; Atlas Daphne; Melamed Eldad; Offen Daniel
A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.
Clinical neuropharmacology 2005;28(6):285-8.
2005: Rascol O; Brooks D J; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet 2005;365(9463):947-54.
2005: Bahat-Stroomza Merav; Gilgun-Sherki Yossi; Offen Daniel; Panet Hana; Saada Ann; Krool-Galron Nili; Barzilai Aari; Atlas Daphne; Melamed Eldad
A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.
The European journal of neuroscience 2005;21(3):637-46.
2005: Kan I; Melamed E; Offen D
Integral therapeutic potential of bone marrow mesenchymal stem cells.
Current drug targets 2005;6(1):31-41.
2005: Gilgun-Sherki Yossi; Barhum Yael; Atlas Daphne; Melamed Eldad; Offen Daniel
Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.
Journal of molecular neuroscience : MN 2005;27(1):125-35.
2005: Levy Yossef S; Gilgun-Sherki Yossi; Melamed Eldad; Offen Daniel
Therapeutic potential of neurotrophic factors in neurodegenerative diseases.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2005;19(2):97-127.
2004: Djaldetti Ruth; Hellmann Mark; Melamed Eldad
Bent knees and tiptoeing: late manifestations of end-stage Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(11):1325-8.
2004: Lorberboym Mordechai; Djaldetti Ruth; Melamed Eldad; Sadeh Menahem; Lampl Yair
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(10):1688-93.
2004: Olanow C Warren; Agid Yves; Mizuno Yoshi; Albanese Alberto; Bonuccelli Ubaldo; Damier Philip; De Yebenes Justo; Gershanik Oscar; Guttman Mark; Grandas F; Hallett Mark; Hornykiewicz Ole; Jenner Peter; Katzenschlager R; Langston William J; LeWitt Peter; Melamed Eldad; Mena M A; Michel P P; Mytilineou Catherine; Obeso Jose A; Poewe Werner; Quinn Niall; Raisman-Vozari R; Rajput Ali H; Rascol Olivier; Sampaio Christina; Stocchi Fabrizio
Levodopa in the treatment of Parkinson's disease: current controversies.
Movement disorders : official journal of the Movement Disorder Society 2004;19(9):997-1005.
2004: Djaldetti R; Shifrin A; Rogowski Z; Sprecher E; Melamed E; Yarnitsky D
Quantitative measurement of pain sensation in patients with Parkinson disease.
Neurology 2004;62(12):2171-5.
2004: Offen Daniel; Gilgun-Sherki Yossi; Barhum Yael; Benhar Moran; Grinberg Leonid; Reich Reuven; Melamed Eldad; Atlas Daphne
A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis.
Journal of neurochemistry 2004;89(5):1241-51.
2004: Lev Nirit; Barhum Yael; Melamed Eldad; Offen Daniel
Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.
Neuroscience letters 2004;359(3):139-42.
2004: Gilgun-Sherki Yossi; Melamed Eldad; Offen Daniel
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.
Journal of neurology 2004;251(3):261-8.
2004: Streifler Jonathan Y; Israel Diana; Melamed Eldad
The hyperperfusion syndrome: an under-recognized complication of carotid endarterectomy.
The Israel Medical Association journal : IMAJ 2004;6(1):54-6.
2004: Elkon Hanoch; Melamed Eldad; Offen Daniel
Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.
Journal of molecular neuroscience : MN 2004;24(3):387-400.
2004: Levy Yossef S; Stroomza Merav; Melamed Eldad; Offen Daniel
Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.
Journal of molecular neuroscience : MN 2004;24(3):353-86.
2004: Gilgun-Sherki Y; Djaldetti R; Melamed E; Offen D
Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.
The pharmacogenomics journal 2004;4(5):291-306.
2003: Djaldetti Ruth; Giladi Nir; Hassin-Baer Sharon; Shabtai Hertzel; Melamed Eldad
Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
Clinical neuropharmacology 2003;26(6):322-6.
2003: Gilgun-Sherki Yossi; Panet Hana; Melamed Eldad; Offen Daniel
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Brain research 2003;989(2):196-204.
2003: Djaldetti Ruth; Lev Nirit; Melamed Eldad
Neuroprotection in progressive brain disorders.
The Israel Medical Association journal : IMAJ 2003;5(8):576-80.
2003: Gilgun-Sherki Yossi; Melamed Eldad; Mechoulam Raphael; Offen Daniel
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Pharmacology & toxicology 2003;93(2):66-70.
2003: Merims Doron; Djaldetti Ruth; Melamed Eldad
Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations.
Clinical neuropharmacology 2003;26(4):196-8.
2003: Gilgun-Sherki Yossi; Melamed Eldad; Ziv Ilan; Offen Daniel
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Pharmacology & toxicology 2003;93(1):54-6.
2003: Lev Nirit; Melamed Eldad; Offen Daniel
Apoptosis and Parkinson's disease.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(2):245-50.
2003: Barzilai Ari; Melamed Eldad
Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease.
Trends in molecular medicine 2003;9(3):126-32.
2003: Djaldetti Ruth; Treves Therese A; Merims Doron; Sroka Hava; Melamed Eldad
Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease.
Clinical neuropharmacology 2003;26(1):24-7.
2003: Levy Yossef S; Merims Doron; Panet Hanna; Barhum Yael; Melamed Eldad; Offen Daniel
Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells.
Journal of molecular neuroscience : MN 2003;21(2):121-32.
2003: Gilgun-Sherki Yossi; Melamed Eldad; Offen Daniel
Antioxidant treatment in Alzheimer's disease: current state.
Journal of molecular neuroscience : MN 2003;21(1):1-11.
2003: Barzilai Ari; Daily Dorah; Zilkha-Falb Rina; Ziv Ilan; Offen Daniel; Melamed Eldad; Shirvan Anat
The molecular mechanisms of dopamine toxicity.
Advances in neurology 2003;91():73-82.
2002: Shirvan Anat; Kimron Michal; Holdengreber Vered; Ziv Ilan; Ben-Shaul Yehuda; Melamed Shlomo; Melamed Eldad; Barzilai Ari; Solomon Arieh S
Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy.
The Journal of biological chemistry 2002;277(51):49799-807.
2002: Djaldetti Ruth; Melamed Eldad
New drugs in the future treatment of Parkinson's disease.
Journal of neurology 2002;249 Suppl 2():II30-5.
2002: Lev Nirit; Melamed Eldad
[Neurological complications in Down's Syndrome]
Harefuah 2002;141(9):820-3, 857.
2002: Hellmann Mark A; Melamed Eldad
Focal dystonia as the presenting sign in Creutzfeldt-Jakob disease.
Movement disorders : official journal of the Movement Disorder Society 2002;17(5):1097-8.
2002: Melamed E; Robinson D; Halperin N; Wallach N; Keren O; Groswasser Z
Brain injury-related heterotopic bone formation: treatment strategy and results.
American journal of physical medicine & rehabilitation / Association of Academic Physiatrists 2002;81(9):670-4.
2002: Elkon Hanock; Don Jermy; Melamed Eldad; Ziv Ilan; Shirvan Anat; Offen Daniel
Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.
Journal of molecular neuroscience : MN 2002;18(3):229-38.
2002: Gilgun-Sherki Yossi; Rosenbaum Ziv; Melamed Eldad; Offen Daniel
Antioxidant therapy in acute central nervous system injury: current state.
Pharmacological reviews 2002;54(2):271-84.
2002: Djaldetti R; Ziv I; Melamed E
The effect of deprenyl washout in patients with long-standing Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(5-6):797-803.
2002: Djaldetti Ruth; Inzelberg Rivkah; Giladi Nir; Korczyn Amos D; Peretz-Aharon Yehudit; Rabey Martin J; Herishano Yuval; Honigman Silvia; Badarny Sami; Melamed Eldad
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2002;17(2):297-302.
2002: Lev Nirit; Michowiz Shalom; Inbar Edna; Coire Claire I; Pitlik Silvio; Melamed Eldad
Neurocysticercosis.
The Israel Medical Association journal : IMAJ 2002;4(1):65-6.
2001: Elkon H; Melamed E; Offen D
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
Cellular and molecular neurobiology 2001;21(6):771-81.
2001: Offen D; Shtaif B; Hadad D; Weizman A; Melamed E; Gil-Ad I
Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease.
Neuroscience letters 2001;316(3):129-32.
2001: Djaldetti R; Melamed E; Gadoth N
Abnormal skin wrinkling in the less affected side in hemiparkinsonism-a possible test for sympathetic dysfunction in Parkinson's disease.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2001;55(8):475-8.
2001: Lev N; Maimon S; Rappaport Z H; Melamed E
Spinal dural arteriovenous fistulae--a diagnostic challenge.
The Israel Medical Association journal : IMAJ 2001;3(7):492-6.
2001: Barzilai A; Melamed E; Shirvan A
Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?
Cellular and molecular neurobiology 2001;21(3):215-35.
2001: Lev N; Melamed E
Heredity in Parkinson's disease: new findings.
The Israel Medical Association journal : IMAJ 2001;3(6):435-8.
2001: Gilgun-Sherki Y; Melamed E; Offen D
Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.
Neuropharmacology 2001;40(8):959-75.
2001: Daily D; Vlamis-Gardikas A; Offen D; Mittelman L; Melamed E; Holmgren A; Barzilai A
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways.
The Journal of biological chemistry 2001;276(24):21618-26.
2001: Djaldetti R; Melamed E
New therapies for Parkinson's disease.
Journal of neurology 2001;248(5):357-62.
2001: Panet H; Barzilai A; Daily D; Melamed E; Offen D
Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells.
Journal of neurochemistry 2001;77(2):391-8.
2001: Djaldetti R; Rosmarin V; Ziv I; Melamed E
The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
Clinical neuropharmacology 2001;24(2):95-8.
2001: Albanese A; Bonuccelli U; Brefel C; Chaudhuri K R; Colosimo C; Eichhorn T; Melamed E; Pollak P; Van Laar T; Zappia M
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2001;16(2):197-201.
2001: Offen D; Panet H; Galili-Mosberg R; Melamed E
Catechol-O-methyltransferase decreases levodopa toxicity in vitro.
Clinical neuropharmacology 2001;24(1):27-30.
2001: Daily D; Vlamis-Gardikas A; Offen D; Mittelman L; Melamed E; Holmgren A; Barzilai A
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1.
The Journal of biological chemistry 2001;276(2):1335-44.
2001: Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Neurologia i neurochirurgia polska 2001;35 Suppl 3():65-8.
2000: Offen D; Kaye J F; Bernard O; Merims D; Coire C I; Panet H; Melamed E; Ben-Nun A
Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).
Journal of molecular neuroscience : MN 2000;15(3):167-76.
2000: Rabey J M; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Clinical neuropharmacology 2000;23(6):324-30.
2000: Melamed E; Keren D; Robinson D; Halperin N; Mrosswasser Z
[Periarticular new bone formation following traumatic brain injury]
Harefuah 2000;139(9-10):368-71.
2000: Shirvan A; Shina R; Ziv I; Melamed E; Barzilai A
Induction of neuronal apoptosis by Semaphorin3A-derived peptide.
Brain research. Molecular brain research 2000;83(1-2):81-93.
2000: Zilkha-Falb R; Barzilai A; Djaldeti R; Ziv I; Melamed E; Shirvan A
Involvement of T-complex protein-1delta in dopamine triggered apoptosis in chick embryo sympathetic neurons.
The Journal of biological chemistry 2000;275(46):36380-7.
2000: Rudnick A; Ezra Y; Melamed E
Breaking bad news and personality assessment.
Patient education and counseling 2000;41(2):157-60.
2000: Merims D; Galili-Mosberg R; Melamed E
Is there addiction to levodopa in patients with Parkinson's disease?
Movement disorders : official journal of the Movement Disorder Society 2000;15(5):1014-6.
2000: Giladi N; Melamed E
The role of functional neurosurgery in Parkinson's disease.
The Israel Medical Association journal : IMAJ 2000;2(6):455-61.
2000: Melamed E; Offen D; Shirvan A; Ziv I
Levodopa--an exotoxin or a therapeutic drug?
Journal of neurology 2000;247 Suppl 2():II135-9.
2000: Lev N; Melamed E
[Sensory symptoms and pain in Parkinson disease]
Harefuah 2000;138(4):324-6.
2000: Hochman A; Liang H; Offen D; Melamed E; Sternin H
Developmental changes in antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice.
Cellular and molecular biology (Noisy-le-Grand, France) 2000;46(1):41-52.
2000: Offen D; Sherki Y; Melamed E; Fridkin M; Brenneman D E; Gozes I
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Brain research 2000;854(1-2):257-62.
2000: Galili R; Mosberg; Gil-Ad I; Weizman A; Melamed E; Offen D
Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(4):479-90.
2000: Barzilai A; Zilkha-Falb R; Daily D; Stern N; Offen D; Ziv I; Melamed E; Shirvan A
The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity.
Journal of neural transmission. Supplementum 2000;(60):59-76.
2000: Offen D; Elkon H; Melamed E
Apoptosis as a general cell death pathway in neurodegenerative diseases.
Journal of neural transmission. Supplementum 2000;(58):153-66.
1999: Lev N; Maimon S; Melamed E; Inbar E; Rappaport Z
[Spinal dural arteriovenous fistula]
Harefuah 1999;137(10):471-4.
1999: Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
[Apomorphine for treatment of "off-periods" in Parkinson's disease]
Harefuah 1999;137(10):444-6, 512, 511.
1999: Agid Y; Ahlskog E; Albanese A; Calne D; Chase T; De Yebenes J; Factor S; Fahn S; Gershanik O; Goetz C; Koller W; Kurth M; Lang A; Lees A; Lewitt P; Marsden D; Melamed E; Michel P P; Mizuno Y; Obeso J; Oertel W; Olanow W; Poewe W; Pollak P; Tolosa E
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Movement disorders : official journal of the Movement Disorder Society 1999;14(6):911-3.
1999: Shirvan A; Ziv I; Fleminger G; Shina R; He Z; Brudo I; Melamed E; Barzilai A
Semaphorins as mediators of neuronal apoptosis.
Journal of neurochemistry 1999;73(3):961-71.
1999: Djaldetti R; Mosberg-Galili R; Sroka H; Merims D; Melamed E
Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon.
Movement disorders : official journal of the Movement Disorder Society 1999;14(3):443-7.
1999: Merims D; Ziv I; Djaldetti R; Melamed E
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
Lancet 1999;353(9166):1764-5.
1999: Daily D; Barzilai A; Offen D; Kamsler A; Melamed E; Ziv I
The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53.
Cellular and molecular neurobiology 1999;19(2):261-76.
1999: Ziv I; Avraham M; Dabby R; Zoldan J; Djaldetti R; Melamed E
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment.
Acta neurologica Scandinavica 1999;99(2):106-11.
1999: Offen D; Gorodin S; Melamed E; Hanania J; Malik Z
Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease.
Neuroscience letters 1999;260(2):101-4.
1999: Giladi N; Melamed E
Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 1999;14(1):158-9.
1999: Melamed E; Olanow C W; Nutt J G; Lang A E
Dyskinesias assessment workshop: reports from the working groups.
Movement disorders : official journal of the Movement Disorder Society 1999;14 Suppl 1():69-73.
1999: Offen D; Hochman A; Gorodin S; Ziv I; Shirvan A; Barzilai A; Melamed E
Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis.
Advances in neurology 1999;80():265-9.
1999: Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
Journal of neural transmission. Supplementum 1999;56():173-83.
1999: Melamed E; Friedberg G; Zoldan J
Psychosis: impact on the patient and family.
Neurology 1999;52(7 Suppl 3):S14-6.
1998: Ziv I; Avraham M; Michaelov Y; Djaldetti R; Dressler R; Zoldan J; Melamed E
Enhanced fatigue during motor performance in patients with Parkinson's disease.
Neurology 1998;51(6):1583-6.
1998: Ziv I; Djaldetti R; Zoldan Y; Avraham M; Melamed E
Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test.
Journal of neurology 1998;245(12):797-802.
1998: Ziv I; Melamed E
Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity?
Movement disorders : official journal of the Movement Disorder Society 1998;13(6):865-70.
1998: Offen D; Halevi S; Orion D; Mosberg R; Stern-Goldberg H; Melamed E; Atlas D
Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels.
Neurology 1998;51(4):1100-3.
1998: Friedberg G; Zoldan J; Weizman A; Melamed E
Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease.
Clinical neuropharmacology 1998;21(5):280-4.
1998: Melamed E; Offen D; Shirvan A; Djaldetti R; Barzilai A; Ziv I
Levodopa toxicity and apoptosis.
Annals of neurology 1998;44(3 Suppl 1):S149-54.
1998: Djaldetti R; Melamed E
Management of response fluctuations: practical guidelines.
Neurology 1998;51(2 Suppl 2):S36-40.
1998: Hochman A; Sternin H; Gorodin S; Korsmeyer S; Ziv I; Melamed E; Offen D
Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice.
Journal of neurochemistry 1998;71(2):741-8.
1998: Djaldetti R; Ziv I; Melamed E
Extreme anticipation in young-onset Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(3):599-600.
1998: Offen D; Beart P M; Cheung N S; Pascoe C J; Hochman A; Gorodin S; Melamed E; Bernard R; Bernard O
Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(10):5789-94.
1998: Shirvan A; Ziv I; Zilkha-Falb R; Machlyn T; Barzilai A; Melamed E
Expression of cell cycle-related genes during neuronal apoptosis: is there a distinct pattern?
Neurochemical research 1998;23(5):767-77.
1997: Shirvan A; Ziv I; Machlin T; Zilkha-Falb R; Melamed E; Barzilai A
Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis.
Journal of neurochemistry 1997;69(2):539-49.
1997: Offen D; Ziv I; Barzilai A; Gorodin S; Glater E; Hochman A; Melamed E
Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease.
Neurochemistry international 1997;31(2):207-16.
1997: Offen D; Ziv I; Panet H; Wasserman L; Stein R; Melamed E; Barzilai A
Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2.
Cellular and molecular neurobiology 1997;17(3):289-304.
1997: Zilkha-Falb R; Ziv I; Nardi N; Offen D; Melamed E; Barzilai A
Monoamine-induced apoptotic neuronal cell death.
Cellular and molecular neurobiology 1997;17(1):101-18.
1997: Ziv I; Zilkha-Falb R; Offen D; Shirvan A; Barzilai A; Melamed E
Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Movement disorders : official journal of the Movement Disorder Society 1997;12(1):17-23.
1997: Ziv I; Offen D; Haviv R; Stein R; Panet H; Zilkha-Falb R; Shirvan A; Barzilai A; Melamed E
The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease.
Apoptosis : an international journal on programmed cell death 1997;2(2):149-55.
1997: Ziv I; Offen D; Barzilai A; Haviv R; Stein R; Zilkha-Falb R; Shirvan A; Melamed E
Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?
Journal of neural transmission. Supplementum 1997;49():195-202.
1997: Ziv I; Barzilai A; Offen D; Nardi N; Melamed E
Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?
Journal of neural transmission. Supplementum 1997;49():69-76.
1997: Shirvan A; Ziv I; Barzilai A; Djaldeti R; Zilkh-Falb R; Michlin T; Melamed E
Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons.
Journal of neural transmission. Supplementum 1997;50():67-78.
1996: Djaldetti R; Ziv I; Melamed E
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
Israel journal of medical sciences 1996;32(12):1224-7.
1996: Djaldetti R; Melamed E
Posttraumatic-delayed cerebellar syndrome.
Archives of neurology 1996;53(12):1214-5.
1996: Offen D; Ziv I; Sternin H; Melamed E; Hochman A
Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.
Experimental neurology 1996;141(1):32-9.
1996: Djaldetti R; Baron J; Ziv I; Melamed E
Gastric emptying in Parkinson's disease: patients with and without response fluctuations.
Neurology 1996;46(4):1051-4.
1996: Djaldetti R; Ziv I; Achiron A; Melamed E
Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment.
Neurology 1996;46(3):632-5.
1996: Djaldetti R; Melamed E
Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
Annals of neurology 1996;39(3):400-4.
1996: Djaldetti R; Atlas D; Melamed E
Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease.
Clinical neuropharmacology 1996;19(1):65-71.
1996: Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
Advances in neurology 1996;69():545-50.
1996: Zoldan J; Friedberg G; Weizman A; Melamed E
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Advances in neurology 1996;69():541-4.
1996: Ziv I; Barzilai A; Offen D; Stein R; Achiron A; Melamed E
Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?
Advances in neurology 1996;69():229-33.
1995: Djaldetti R; Achiron A; Ziv I; Djaldetti M; Melamed E; Fishman P
IL-3-LA production by mononuclear cells of patients with multiple sclerosis: effect of treatment with intravenous immunoglobulins.
Immunological investigations 1995;24(5):765-73.
1995: Offen D; Ziv I; Gorodin S; Barzilai A; Malik Z; Melamed E
Dopamine-induced programmed cell death in mouse thymocytes.
Biochimica et biophysica acta 1995;1268(2):171-7.
1995: Zoldan J; Friedberg G; Livneh M; Melamed E
Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist.
Neurology 1995;45(7):1305-8.
1995: Nerurkar V R; Achiron A; Song K J; Melland R R; Pinhas-Hamiel O; Melamed E; Shohat B; Yanagihara R
Human T-cell lymphotropic virus type I in Iranian-born Mashhadi Jews: genetic and phylogenetic evidence for common source of infection.
Journal of medical virology 1995;45(4):361-6.
1995: Djaldetti R; Koren M; Ziv I; Achiron A; Melamed E
Effect of cisapride on response fluctuations in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1995;10(1):81-4.
1995: Achiron A; Cohen I R; Lider O; Melamed E
Intravenous immunoglobulin treatment in multiple sclerosis.
Israel journal of medical sciences 1995;31(1):7-9.
1995: Melamed E
Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
Journal of neural transmission. Supplementum 1995;45():57-60.
1994: Achiron A; Gilad R; Margalit R; Gabbay U; Sarova-Pinhas I; Cohen I R; Melamed E; Lider O; Noy S; Ziv I
Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.
Journal of neurology, neurosurgery, and psychiatry 1994;57 Suppl():57-61.
1994: Ziv I; Achiron A; Djaldetti R; Abraham M; Melamed E
Can nimodipine affect progression of motor neuron disease? A double-blind pilot study.
Clinical neuropharmacology 1994;17(5):423-8.
1994: Djaldetti R; Achiron A; Ziv I; Melamed E
First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):582-3.
1994: Goldberg-Stern H; D'jaldetti R; Melamed E; Gadoth N
Machado-Joseph (Azorean) disease in a Yemenite Jewish family in Israel.
Neurology 1994;44(7):1298-301.
1994: Goldberg-Stern H; Melamed E; Gadoth N
Abnormal evoked potentials in Miller-Fisher syndrome: further evidence of combined peripheral and central demyelination.
Journal of neurology, neurosurgery, and psychiatry 1994;57(4):506.
1994: Tanner C M; Melamed E; Lees A J
Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease.
Neurology 1994;44(3 Suppl 1):S12-6.
1994: Ziv I; Melamed E; Nardi N; Luria D; Achiron A; Offen D; Barzilai A
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.
Neuroscience letters 1994;170(1):136-40.
1993: Achiron A; Pinhas-Hamiel O; Doll L; Djaldetti R; Chen A; Ziv I; Avni A; Frankel G; Melamed E; Shohat B
Spastic paraparesis associated with human T-lymphotropic virus type I: a clinical, serological, and genomic study in Iranian-born Mashhadi Jews.
Annals of neurology 1993;34(5):670-5.
1993: Achiron A; Ziv I; Goren M; Goldberg H; Zoldan Y; Sroka H; Melamed E
Primary progressive freezing gait.
Movement disorders : official journal of the Movement Disorder Society 1993;8(3):293-7.
1993: Ziv I; Achiron A; Djaldetti R; Dressler R; Melamed E
Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment.
Clinical neuropharmacology 1993;16(1):54-60.
1993: Zoldan J; Friedberg G; Goldberg-Stern H; Melamed E
Ondansetron for hallucinosis in advanced Parkinson's disease.
Lancet 1993;341(8844):562-3.
1993: Goldberg-Stern H; Atlas D; Schwartz L; Achiron A; Ziv I; Djaldetti R; Zoldan Y; Melamed E
Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid.
Brain research 1993;601(1-2):325-8.
1992: Achiron A; Pras E; Gilad R; Ziv I; Mandel M; Gordon C R; Noy S; Sarova-Pinhas I; Melamed E
Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis.
Archives of neurology 1992;49(12):1233-6.
1992: Achiron A; Ziv I; Djaldetti R; Goldberg H; Kuritzky A; Melamed E
Aphasia in multiple sclerosis: clinical and radiologic correlations.
Neurology 1992;42(11):2195-7.
1992: Djaldetti R; Ziv I; Achiron A; Melamed E
Parkinson's disease in a patient with mitochondrial myopathy: is there a causative relationship?
Movement disorders : official journal of the Movement Disorder Society 1992;7(4):382-3.
1992: Kuritzky A; Zoldan Y; Melamed E
Selegeline, a MAO B inhibitor, is not effective in the prophylaxis of migraine without aura--an open study.
Headache 1992;32(8):416.
1992: Ziv I; Fleminger G; Djaldetti R; Achiron A; Melamed E; Sokolovsky M
Increased plasma endothelin-1 in acute ischemic stroke.
Stroke; a journal of cerebral circulation 1992;23(7):1014-6.
1992: Melamed E
Biochemical and functional differences between dopamine formed from endogenous tyrosine and exogenous L-dopa in nigrostriatal dopaminergic neurons.
Neurochemistry international 1992;20 Suppl():115S-117S.
1991: Melamed E; Achiron A; Shapira A; Davidovicz S
Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?
Clinical neuropharmacology 1991;14(3):273-8.
1990: Michowiz S D; Melamed E; Pikarsky E; Rappaport Z H
Effect of ischemia induced by middle cerebral artery occlusion on superoxide dismutase activity in rat brain.
Stroke; a journal of cerebral circulation 1990;21(11):1613-7.
1990: Melamed E; Rosenthal J; Youdim M B
Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Journal of neurochemistry 1990;55(4):1427-31.
1990: Achiron A; Ziv I; Melamed E
[Aluminium and Alzheimer's disease]
Harefuah 1990;118(11):674-5.
1990: Achiron A; Zoldan Y; Melamed E
Tardive dyskinesia induced by sulpiride.
Clinical neuropharmacology 1990;13(3):248-52.
1990: Achiron A; Gornish M; Melamed E
Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.
Stroke; a journal of cerebral circulation 1990;21(5):817-9.
1990: Arber N; Shirin H; Fadila R; Melamed E; Pinkhas J; Sidi Y
Pseudotumor cerebri associated with leuprorelin acetate.
Lancet 1990;335(8690):668.
1990: Achiron A; Melamed E
Tardive eating dystonia.
Movement disorders : official journal of the Movement Disorder Society 1990;5(4):331-3.
1990: Melamed E
Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Advances in neurology 1990;53():61-6.
1989: Achiron A; Mendel M; Rechavi G; Ramot B; Melamed E
Changes in T-cell subpopulations in multiple sclerosis.
Annals of neurology 1989;26(2):291-2.
1989: Gadoth N; Abramovitch D; Melamed E
The regional cerebral blood flow in familial dysautonomia.
Brain & development 1989;11(3):179-82.
1988: Feldman S; Conforti N; Melamed E
Hypothalamic norepinephrine mediates limbic effects on adrenocortical secretion.
Brain research bulletin 1988;21(4):587-90.
1988: Siegal T; Melamed E; Sandbank U; Catane R
Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection.
Journal of neuro-oncology 1988;6(2):135-40.
1988: Melamed E
Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease.
Clinical neuropharmacology 1988;11(1):77-82.
1988: Feldman S; Conforti N; Melamed E
Involvement of ventral noradrenergic bundle in corticosterone secretion following neural stimuli.
Neuropharmacology 1988;27(2):129-33.
1988: Melamed E
Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
The Mount Sinai journal of medicine, New York 1988;55(1):35-42.
1987: Melamed E; Soffer D; Rosenthal J; Pikarsky E; Reches A
Effect of intrastriatal and intranigral administration of synthetic neuromelanin on the dopaminergic neurotoxicity of MPTP in rodents.
Neuroscience letters 1987;83(1-2):41-6.
1987: Pikarsky E; Melamed E; Rosenthal J; Uzzan A; Michowiz S D
The neurotoxin MPTP does not affect striatal superoxide dismutase activity in mice.
Neuroscience letters 1987;82(3):327-31.
1987: Steiner I; Shahin R; Melamed E
Acute "upside down" reversal of vision in transient vertebrobasilar ischemia.
Neurology 1987;37(10):1685-6.
1987: Gottlieb D; Mildworf B; Rubinger D; Melamed E
The regional cerebral blood flow in patients under chronic hemodialytic treatment.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1987;7(5):659-61.
1987: Melamed E; Mildworf B; Sharav T; Belenky L; Wertman E
Regional cerebral blood flow in Down's syndrome.
Annals of neurology 1987;22(2):275-8.
1987: Kidron D; Melamed E
Forms of dystonia in patients with Parkinson's disease.
Neurology 1987;37(6):1009-11.
1987: Fishman R H; Pleet A B; Melamed E; Abramsky O
Regional brain superoxide dismutase activity is altered differently by heat in warm and cool mice.
Brain research 1987;410(2):343-6.
1987: Feldman S; Conforti N; Melamed E
Paraventricular nucleus serotonin mediates neurally stimulated adrenocortical secretion.
Brain research bulletin 1987;18(2):165-8.
1987: Melamed E; Globus M; Rosenthal J; Uzzan A
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
Advances in neurology 1987;45():507-10.
1987: Kidron D; Steiner I; Melamed E
Late-onset progressive radiculomyelopathy in patients with cervical athetoid-dystonic cerebral palsy.
European neurology 1987;27(3):164-6.
1986: Soffer D; Melamed E; Assaf Y; Cotev S
Hemispheric brain damage in unilateral status epilepticus.
Annals of neurology 1986;20(6):737-40.
1986: Melamed E; Pikarski E; Goldberg A; Rosenthal J; Uzzan A; Conforti N
Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in mice.
Brain research 1986;399(1):178-80.
1986: Melamed E; Globus M; Mildworf B
Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations.
Journal of neurology, neurosurgery, and psychiatry 1986;49(11):1301-4.
1986: Gottlieb D; Fields S; Bitton V; Gomori M; Kidron D; Melamed E
[Clinical-roentgenological study of degenerative spinocerebellar diseases]
Harefuah 1986;111(7-8):165-7.
1986: Melamed E; Martinovits G; Pikarsky E; Rosenthal J; Uzzan A
Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice.
European journal of pharmacology 1986;128(3):255-7.
1986: Martinovits G; Melamed E; Cohen O; Rosenthal J; Uzzan A
Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP).
Neuroscience letters 1986;69(2):192-7.
1986: Feldman S; Conforti N; Melamed E
Noradrenergic mediation of adrenocortical responses following cortical stimulation in the rat.
Israel journal of medical sciences 1986;22(7-8):591-3.
1986: Mildworf B; Globus M; Melamed E
[Measurement of cognitive functions in Parkinson's disease]
Harefuah 1986;110(10):501-3.
1986: Melamed E; Frucht Y; Vidauri J; Uzzan A; Rosenthal J
Effect of postnatal light deprivation on the ontogenesis of dopamine neurons in rat retina.
Brain research 1986;391(2):280-4.
1986: Melamed E
Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease.
Archives of neurology 1986;43(4):402-5.
1986: Baum M J; Melamed E; Globus M
Dissociation of the effects of castration and testosterone replacement on sexual behavior and neural metabolism of dopamine in the male rat.
Brain research bulletin 1986;16(2):145-8.
1986: Feldman S; Conforti N; Melamed E
Norepinephrine depletion in the paraventricular nucleus inhibits the adrenocortical responses to neural stimuli.
Neuroscience letters 1986;64(2):191-5.
1986: Melamed E; Bitton V; Zelig O
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
Neurology 1986;36(1):100-3.
1986: Melamed E; Bitton V; Zelig O
Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
Clinical neuropharmacology 1986;9(2):182-8.
1985: Melamed E; Youdim M B; Rosenthal J; Spanier I; Uzzan A; Globus M
In vivo effect of MPTP on monoamine oxidase activity in mouse striatum.
Brain research 1985;359(1-2):360-3.
1985: Melamed E; Youdim M B
Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
British journal of pharmacology 1985;86(3):529-31.
1985: Melamed E; Rosenthal J; Cohen O; Globus M; Uzzan A
Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
European journal of pharmacology 1985;116(1-2):179-81.
1985: Melamed E; Rosenthal J; Cohen O; Uzzan A; Globus M
Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP.
Neuropharmacology 1985;24(9):923-5.
1985: Melamed E; Rosenthal J; Globus M; Cohen O; Uzzan A
Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.
Brain research 1985;342(2):401-4.
1985: Globus M; Melamed E
Progressive age-related decrease in regional cerebral blood flow in healthy subjects.
Israel journal of medical sciences 1985;21(8):662-5.
1985: Globus M; Mildworf B; Melamed E
Cerebral blood flow and cognitive impairment in Parkinson's disease.
Neurology 1985;35(8):1135-9.
1985: Melamed E; Rosenthal J; Globus M; Cohen O; Frucht Y; Uzzan A
Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice.
European journal of pharmacology 1985;114(1):97-100.
1985: Yanai J; Sze P Y; Iser C; Melamed E
Studies on brain monoamine neurotransmitters in mice after prenatal exposure to barbiturate.
Pharmacology, biochemistry, and behavior 1985;23(2):215-9.
1985: Barash V; Globus M; Melamed E; Weidenfeld J
Effect of L-DOPA on glucose oxidation and incorporation into glycogen in discrete brain regions of the rat.
Brain research 1985;335(2):347-9.
1985: Melamed E; Hefti F
Altered pharmacokinetics of L-dopa metabolism.
Neurology 1985;35(6):939-41.
1985: Steiner I; Gomori J M; Melamed E
Progressive brain atrophy during normal aging in man: a quantitative computerized tomography study.
Israel journal of medical sciences 1985;21(3):279-82.
1985: Freund H R; Muggia-Sullam M; Peiser J; Melamed E
Brain neurotransmitter profile is deranged during sepsis and septic encephalopathy in the rat.
The Journal of surgical research 1985;38(3):267-71.
1985: Steiner I; Argov Z; Gomori J M; Gottlieb D; Melamed E
Immediate spasticity with acute hemiplegia is a sign of basal ganglia hemorrhage.
Acta neurologica Scandinavica 1985;71(2):168-70.
1985: Siegal T; Mildworf B; Stein D; Melamed E
Leptomeningeal metastases: reduction in regional cerebral blood flow and cognitive impairment.
Annals of neurology 1985;17(1):100-2.
1985: Hefti F; Enz A; Melamed E
Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs.
Neuropharmacology 1985;24(1):19-23.
1985: Steiner I; Gomori J M; Melamed E
Features of brain atrophy in Parkinson's disease. A CT scan study.
Neuroradiology 1985;27(2):158-60.
1984: Melamed E; Hefti F; Bitton V; Globus M
Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
Neurology 1984;34(12):1566-70.
1984: Steiner I; Melamed E
Conjugate eye deviation after acute hemispheric stroke: delayed recovery after previous contralateral frontal lobe damage.
Annals of neurology 1984;16(4):509-11.
1984: Feldman S; Melamed E; Conforti N; Weidenfeld J
Effect of central serotonin depletion on adrenocortical responses to neural stimuli.
Experimental neurology 1984;85(3):661-6.
1984: Melamed E; Frucht Y; Lemor M; Uzzan A; Rosenthal Y
Dopamine turnover in rat retina: a 24-hour light-dependent rhythm.
Brain research 1984;305(1):148-51.
1984: Berger J R; Sheremata W A; Melamed E
Paroxysmal dystonia as the initial manifestation of multiple sclerosis.
Archives of neurology 1984;41(7):747-50.
1984: Wertman E; Melamed E
[Senile dementia--recent developments]
Harefuah 1984;107(1-2):39-42.
1984: Frucht Y; Melamed E
The dopaminergic amacrine system and its response to light stimulation in rats with inherited retinal dystrophy.
Experimental eye research 1984;38(4):391-8.
1984: Steiner I; Gomori J M; Melamed E
The prognostic value of the CT scan in conservatively treated patients with intracerebral hematoma.
Stroke; a journal of cerebral circulation 1984;15(2):279-82.
1984: Steiner I; Polacheck I; Melamed E
Dementia and myoclonus in a case of cryptococcal encephalitis.
Archives of neurology 1984;41(2):216-7.
1984: Feldman S; Siegel R A; Weidenfeld J; Conforti N; Melamed E
Adrenocortical responses to ether stress and neural stimuli in rats following the injection of 6-hydroxydopamine into the medial forebrain bundle.
Experimental neurology 1984;83(1):215-20.
1984: Bitton V; Melamed E
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
The Journal of clinical psychiatry 1984;45(1):28-30.
1984: Gomori J M; Steiner I; Melamed E; Cooper G
The assessment of changes in brain volume using combined linear measurements. A CT-scan study.
Neuroradiology 1984;26(1):21-4.
1984: Globus M; Cooper G; Melamed E
Reduction in regional cerebral blood flow during normal aging is not limited to elderly subjects.
Monographs in neural sciences 1984;11():139-43.
1984: Melamed E; Hefti F
Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
Advances in neurology 1984;40():149-57.
1984: Feldman S; Melamed E; Conforti N; Weidenfeld J
Inhibition in corticotrophin and corticosterone secretion following photic stimulation in rats with 6-hydroxydopamine injection into the medial forebrain bundle.
Journal of neuroscience research 1984;12(1):87-92.
1983: Steiner I; Melamed E
Folic acid and the nervous system.
Neurology 1983;33(12):1634.
1983: Steiner I; Melamed E
[Steroid treatment in brain edema]
Harefuah 1983;105(12):432-4.
1983: Globus M; Melamed E; Keren A; Tzivoni D; Granot C; Lavy S; Stern S
Effect of exercise on cerebral circulation.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1983;3(3):287-90.
1983: Siegel R A; Weidenfeld J; Chen M; Feldman S; Melamed E; Chowers I
Hippocampal cell nuclear binding of corticosterone following 5,7-dihydroxytryptamine.
Molecular and cellular endocrinology 1983;31(2-3):253-9.
1983: Melamed E; Globus M; Friedlender E; Rosenthal J
Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections.
Neurology 1983;33(7):950-3.
1983: Feldman S; Siegel R A; Weidenfeld J; Conforti N; Melamed E
Adrenocortical secretion following photic stimulation mediated by medial forebrain bundle catecholaminergic fibers.
Israel journal of medical sciences 1983;19(7):662-4.
1983: Melamed E; Durst R; Frucht Y; Globus M
Differential effect of acute and chronic haloperidol administration on dopamine turnover in rat nigrostriatal and retinal dopaminergic neurons.
European journal of pharmacology 1983;89(3-4):279-82.
1983: Feldman S; Siegel R A; Weidenfeld J; Conforti N; Melamed E
Role of medial forebrain bundle catecholaminergic fibers in the modulation of glucocorticoid negative feedback effects.
Brain research 1983;260(2):297-300.
1983: Globus M; Melamed E; Conforti N
Effect of decortication on striatal dopamine turnover.
Clinical neuropharmacology 1983;6(3):247-52.
1983: Globus M; Melamed E
Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.
Progress in neuro-psychopharmacology & biological psychiatry 1983;7(2-3):211-5.
1982: Globus M; Melamed E; Keren A; Tzivoni D; Stern S
[Cerebral blood flow in hypertension]
Harefuah 1982;103(10):240-2.
1982: Melamed E
[Regional cerebral blood flow in the aging human brain and in Alzheimer's dementia and Parkinson's disease]
Harefuah 1982;103(10):234-6.
1982: Lichtensteiger W; Hefti F; Felix D; Huwyler T; Melamed E; Schlumpf M
Stimulation of nigrostriatal dopamine neurones by nicotine.
Neuropharmacology 1982;21(10):963-8.
1982: Frucht Y; Vidauri J; Melamed E
Light activation of dopaminergic neurons in rat retina is mediated through photoreceptors.
Brain research 1982;249(1):153-6.
1982: Melamed E; Hefti F; Bird E D
Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions.
Neurology 1982;32(6):640-4.
1982: Growdon J H; Melamed E; Logue M; Hefti F; Wurtman R J
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease.
Life sciences 1982;30(10):827-32.
1982: Melamed E; Hefti F; Wurtman R J
Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Israel journal of medical sciences 1982;18(1):159-63.
1981: Hefti F; Melamed E
Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry.
Brain research 1981;225(2):333-46.
1981: Melamed E; Hefti F; Pettibone D J; Liebman J; Wurtman R J
Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism.
Neurology 1981;31(6):651-5.
1981: Hefti F; Melamed E; Wurtman R J
The site of dopamine formation in rat striatum after L-dopa administration.
The Journal of pharmacology and experimental therapeutics 1981;217(1):189-97.
1980: Melamed E; Hefti F; Wurtman R J
Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
Annals of neurology 1980;8(6):558-63.
1980: Wurtman R J; Hefti F; Melamed E
Precursor control of neurotransmitter synthesis.
Pharmacological reviews 1980;32(4):315-35.
1980: Melamed E; Hefti F; Wurtman R J
Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries.
Brain research 1980;198(1):244-8.
1980: Hefti F; Melamed E; Wurtman R J
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.
Brain research 1980;195(1):123-37.
1980: Melamed E; Hefti F; Wurtman R J
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(7):4305-9.
1980: Melamed E; Hefti F; Wurtman R J
L-3,4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotoninergic input.
Journal of neurochemistry 1980;34(6):1753-6.
1980: Melamed E; Hefti F; Wurtman R J
Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid.
Neuropharmacology 1980;19(4):409-11.
1980: Hefti F; Melamed E; Sahakian B J; Wurtman R J
Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.
Pharmacology, biochemistry, and behavior 1980;12(2):185-8.
1980: Melamed E; Hefti F; Liebman J; Schlosberg A J; Wurtman R J
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Nature 1980;283(5749):772-4.
1980: Lavy S; Stern S; Melamed E; Cooper G; Keren A; Levy P
Effect of chronic atrial fibrillation on regional cerebral blood flow.
Stroke; a journal of cerebral circulation 1980;11(1):35-8.
1980: Melamed E; Lavy S; Bentin S; Cooper G; Rinot Y
Reduction in regional cerebral blood flow during normal aging in man.
Stroke; a journal of cerebral circulation 1980;11(1):31-5.
1980: Melamed E; Glaeser B; Growdon J H; Wurtman R J
Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals.
Journal of neural transmission 1980;47(4):299-306.
1980: Hefti F; Melamed E; Wurtman R J
The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model.
Journal of neural transmission. Supplementum 1980;(16):95-101.
1979: Moskowitz M A; Reinhard J F; Romero J; Melamed E; Pettibone D J
Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine?
Lancet 1979;2(8148):883-5.
1979: Lavy S; Melamed E; Cooper G; Bentin S; Rinot Y
Regional cerebral blood flow in patients with Parkinson's disease.
Archives of neurology 1979;36(6):344-8.
1979: Melamed E
Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease.
Archives of neurology 1979;36(5):308-10.
1979: Berger J R; Globus M; Melamed E
Acute transitory cerebellar dysfunction associated with piperazine adipate.
Archives of neurology 1979;36(3):180-1.
1979: Melamed E; Larsen B
Cortical activation pattern during saccadic eye movements in humans: localization by focal cerebral blood flow increases.
Annals of neurology 1979;5(1):79-88.
1979: Argov Z; Melamed E; Katz S
Hyperparathyroidism presenting with unusual neurological features.
European neurology 1979;18(5):338-40.
1979: Melamed E; Lavy S
Effect of papaverine on regional cerebral blood flow of the contralateral hemisphere in patients with acute cerebral infarction.
Applied neurophysiology 1979;42(4):217-23.
1978: Melamed E; Korn-Lubetzki I; Reches A; Siew F
Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan.
Annals of neurology 1978;4(6):582.
1978: Lavy S; Melamed E; Bentin S; Cooper G; Rinot Y
Bihemispheric decreases of regional cerebral blood flow in dementia: correlation with age-matched normal controls.
Annals of neurology 1978;4(5):445-50.
1978: Melamed E; Lavy S; Cooper G; Bentin S
Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa.
Journal of the neurological sciences 1978;38(3):391-7.
1978: Melamed E; Lavy S; Siew F; Bentin S; Cooper G
Correlation between regional cerebral blood flow and brain atrophy in dementia. Combined study with 133Xenon inhalation and computerised tomography.
Journal of neurology, neurosurgery, and psychiatry 1978;41(10):894-9.
1978: Yarnell P; Melamed E; Silverberg R
Global hemianaesthesia: a parietal perceptual distortion suggesting non-organic illness.
Journal of neurology, neurosurgery, and psychiatry 1978;41(9):843-6.
1978: Melamed E; Luhar M; Atlas D
Histochemical labeling of beta-adrenergic receptors in the mouse central nervous system by 9-amino-acridin propranolol.
Neurology 1978;28(8):850-3.
1978: Atlas D; Melamed E
Direct mapping of beta-adrenergic receptors in the rat central nervous system by a novel fluorescent beta-blocker.
Brain research 1978;150(2):377-85.
1977: Melamed E; Lahav M; Atlas D
beta-Adrenergic receptors in rat cerebral cortex: histochemical localization by a fluorescent beta-blocker.
Brain research 1977;128(2):379-84.
1977: Melamed E; Lavy S
Parkinsonism associated with chronic inhalation of carbon tetrachloride.
Lancet 1977;1(8019):1015.
1977: Melamed E; Atlas D; Lahav M
Direct evidence for absence of beta-adrenergic receptors in rat cerebral vessels histochemical study with a fluorescent beta-blocker.
Stroke; a journal of cerebral circulation 1977;8(2):261-3.
1977: Lavy S; Melamed E; Portnoy Z; Carmon A
Regional cerebral blood flow in the epileptic brain during the seizure-free interval.
Acta neurologica Scandinavica. Supplementum 1977;64():232-3.
1977: Melamed E; Larsen B
Regional cerebral blood flow during voluntary conjugate eye movements in man.
Acta neurologica Scandinavica. Supplementum 1977;64():530-1.
1977: Lassen N A; Roland P E; Larsen B; Melamed E; Soh K
Mapping of human cerebral functions: a study of the regional cerebral blood flow pattern during rest, its reproducibility and the activations seen during basic sensory and motor functions.
Acta neurologica Scandinavica. Supplementum 1977;64():262-3, 274-5.
1977: Lavy S; Melamed E; Portnoy Z
Cerebral blood flow response in non affected hemisphere of patients with acute cerebral infarction.
Acta neurologica Scandinavica. Supplementum 1977;64():246-7.
1976: Melamed E; Lahav M; Atlas D
Histochemical evidence for beta-adrenergic receptors in the rat spinal cord.
Brain research 1976;116(3):511-5.
1976: Melamed E
Reactive hyperglycaemia in patients with acute stroke.
Journal of the neurological sciences 1976;29(2-4):267-75.
1976: Melamed E; Reches A
Internal carotid arterial occlusion simulating extracerebral hematoma: relation to diagnosis of stroke.
Journal of the American Geriatrics Society 1976;24(7):317-22.
1976: Melamed E; Lahav M; Atlas D
Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol.
Nature 1976;261(5559):420-2.
1976: Lavy S; Melamed E; Portnoy Z; Carmon A
Interictal regional cerebral blood flow in patients with partial seizures.
Neurology 1976;26(5):418-22.
1976: Melamed E; Rachmilewitz E A; Reches A; Lavy S
Aseptic cavernous sinus thrombosis after internal carotid arterial occlusion in polycythaemia vera.
Journal of neurology, neurosurgery, and psychiatry 1976;39(4):320-4.
1975: Melamed E; Lavy S; Portnoy Z
Regional cerebral blood flow response to hypocapnia in the contralateral hemisphere of patients with acute cerebral infarction.
Stroke; a journal of cerebral circulation 1975;6(5):503-8.
1975: Melamed E; Lavy S; Portnoy Z; Sadan S; Carmon A
Correlation between regional cerebral blood flow and EEG frequency in the contralateral hemisphere in acute cerebral infarction.
Journal of the neurological sciences 1975;26(1):21-7.
1975: Melamed E; Reches A; Hershko C
Reversible central nervous system dysfunction in folate deficiency.
Journal of the neurological sciences 1975;25(1):93-8.
1975: Lavy S; Melamed E; Portnoy Z
The effect of cerebral infarction on the regional cerebral blood flow of the contralateral hemisphere.
Stroke; a journal of cerebral circulation 1975;6(2):160-3.
1975: Melamed E; Lavy S; Reches A; Sahar A
Chronic subdural hematoma simulating transient cerebral ischemic attacks. Case report.
Journal of neurosurgery 1975;42(1):101-3.
1975: Abraham F A; Melamed E; Lavy S
Prognostic value of visual evoked potentials in occipital blindness following basilar artery occlusion.
Applied neurophysiology 1975;38(2):126-35.
1975: Melamed E; Cohen C; Soffer D; Lavy S
Central nervous system complication in a patient with chronic gaucher's disease.
European neurology 1975;13(2):167-75.
1974: Lavy S; Yaar I; Melamed E; Stern S
The effect of acute stroke on cardiac functions as observed in an intensive stroke care unit.
Stroke; a journal of cerebral circulation 1974;5(6):775-80.
1974: Melamed E; Abraham F A; Lavy S
Cortical blindness as a manifestation of basilar artery occlusion.
European neurology 1974;11(1):22-9.
1973: Lavy S; Melamed E; Cahane E; Carmon A
Hypertension and diabetes as risk factors in stroke patients.
Stroke; a journal of cerebral circulation 1973;4(5):751-9.
1973: Melamed E; Cahane E; Carmon A; Lavy S
Stroke in Jerusalem district 1960 through 1967: an epidemiological study.
Stroke; a journal of cerebral circulation 1973;4(3):465-71.

Sign-in to see more